Ampio Pharmaceuticals Inc.
| AMEX: AMPE | Healthcare / Biotechnology / USA |
| 3.68 | +0.0600 | +1.66% | Vol 5.93K | 1Y Perf 6 098.63% |
| Oct 3rd, 2023 15:59 DELAYED |
| BID | 3.68 | ASK | 3.74 | ||
| Open | 3.66 | Previous Close | 3.62 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 2.50 | Analyst Rating | — 0.00 | |
| Potential % | -32.07 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.14 | Earnings Rating | Buy | |
| Market Cap | 2.78M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.26 | |
| Beta | 1.78 |
Today's Price Range 3.653.94 | 52W Range 3.3518.60 | 5 Year PE Ratio Range -5.301.70 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.00% | ||
| 1 Month | 1 709.10% | ||
| 3 Months | 1 439.12% | ||
| 6 Months | 1 535.79% | ||
| 1 Year | 6 098.63% | ||
| 3 Years | 314.09% | ||
| 5 Years | 596.15% | ||
| 10 Years | -52.18% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -397.11 | |||
ROE last 12 Months | -130.71 | |||
ROA (5Y Avg) | -34.89 | |||
ROA last 12 Months | -98.48 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -124.68 | |||
Return on invested Capital Q | -36.66 | |||
Return on invested Capital Y | -26.78 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 0.32 | ||||
| - | ||||
| - | ||||
| -0.30 | ||||
| -1.37 | ||||
| 0.32 | ||||
| 0.92 | ||||
| -11 876 600.00 | ||||
| Forward PE | -45.50 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.30 | ||||
| 4.70 | ||||
| 0.03 | ||||
| 0.05 | ||||
| - | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -0.09 | - |
| Q03 2022 | - | -0.50 | - |
| Q02 2022 | -0.30 | -0.30 | 0.00 |
| Q01 2022 | -0.30 | -0.45 | -50.00 |
| Q04 2021 | -0.30 | -0.60 | -100.00 |
| Q03 2021 | -0.30 | -0.30 | 0.00 |
| Q02 2021 | -0.30 | -0.30 | 0.00 |
| Q01 2021 | -0.02 | -0.02 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -0.02 | 0.00 | - |
| 9/2022 QR | -0.02 | 0.00 | - |
| 12/2022 FY | -0.08 | 11.11 | Positive |
| 12/2023 FY | -0.08 | 0.00 | - |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 5.93K |
| Shares Outstanding | 755 |
| Shares Float | 689.27K |
| Trades Count | 214 |
| Dollar Volume | 22.20K |
| Avg. Volume | 197.26K |
| Avg. Weekly Volume | 13.37K |
| Avg. Monthly Volume | 126.20K |
| Avg. Quarterly Volume | 452.21K |
Ampio Pharmaceuticals Inc. (AMEX: AMPE) stock closed at 3.62 per share at the end of the most recent trading day (a -0.55% change compared to the prior day closing price) with a volume of 7.88K shares and market capitalization of 2.78M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. Ampio Pharmaceuticals Inc. CEO is Michael E. Macaluso.
The one-year performance of Ampio Pharmaceuticals Inc. stock is 6098.63%, while year-to-date (YTD) performance is 1507.46%. AMPE stock has a five-year performance of 596.15%. Its 52-week range is between 3.354 and 18.6, which gives AMPE stock a 52-week price range ratio of 2.14%
Ampio Pharmaceuticals Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.32, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -98.48%, a ROC of -124.68% and a ROE of -130.71%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Ampio Pharmaceuticals Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Ampio Pharmaceuticals Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Ampio Pharmaceuticals Inc. is — (0), with a target price of $2.5, which is -32.07% compared to the current price. The earnings rating for Ampio Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Ampio Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Ampio Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.86, ATR14 : 0.34, CCI20 : 22.88, Chaikin Money Flow : 0.25, MACD : 0.79, Money Flow Index : 57.39, ROC : -13.19, RSI : 69.95, STOCH (14,3) : 0.63, STOCH RSI : 0.00, UO : 22.05, Williams %R : -99.37), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Ampio Pharmaceuticals Inc. in the last 12-months were: David R. Stevens (Buy at a value of $15 400), J. Kevin Buchi (Buy at a value of $39 255), Martino Michael (Buy at a value of $22 298)
Ampio Pharmaceuticals Inc.
Ampio Pharmaceuticals Inc is a biopharmaceutical company. The company focused primarily on developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process and decreasing vascular permeability. Ampio's leading product candidates are Ampion and Optina. It is currently conducting the second pivotal clinical trial in the United States for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.
CEO: Michael E. Macaluso
Telephone: +1 720 437-6500
Address: 373 Inverness Parkway, Englewood 80112, CO, US
Number of employees: 23
